Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Cogentin recall

Executive Summary

Company recalling certain production lots of the supplemental Parkinson's Disease drug benztropin mesylate in 1 mg and 2 mg tablets because quality control testing showed that some tablet samples from previously released lots of medication may no longer meet the requirements for the specified amount of active ingredient. Merck says that it expects FDA to classify the recall of the supplemental Parkinson's disease medication as a Class III recall. The recall is the second for Merck this year. Earlier, the company recalled lots of the diuretic HydroDiuril.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel